Over the past decade a plethora of digital formats have begun competing with print, television, radio and conferences for biopharma marketeers' budgets. And while initial uptake was slow, a survey has now found Big Data, social media and mobile have doubled their share of the marketing mix since 2012.
The United Kingdom's long history of public healthcare gives it an enviable trove of patient data. Yet this resource, which is perhaps the one true competitive edge possessed by U.K. biopharma, is at risk of being squandered as the project continues to buried by mismanagement and a blizzard of negative publicity.
Last year 18 universities, companies and government agencies founded the National Consortium for Data Science. The consortium has a broad brief but soon established the challenges and potential of Big Data are writ largest in one field--genomics.
GlaxoSmithKline, Pfizer and Roche have each taken steps to open up their clinical trial data, but each has faced criticism for leaving loopholes in their policies. Johnson & Johnson has now gone one step further by taking itself out of data-sharing decisions completely.
Clinical trials have increased in complexity over the past decade, with sponsors working with an increasing number of sites, countries and service providers. These massive globalized studies place new strains on the organization of essential study documents, collectively known as the trial master file.
Inherent conservatism and a lack of regulatory guidance have caused pharma to edge slowly onto social media platforms. Yet patients still talk about their health online. Should drugmakers be listening?
At the J.P. Morgan Healthcare Conference this week, Illumina unveiled a system to kick-start the era of low-cost, industrial-scale sequencing of human genomes.
Open-source companies have had a big impact on parts of IT. The model is being used by Rackspace in cloud computing, Acquia in content management and Red Hat in operating systems. Now a startup out of Harvard Medical School is applying the model to bio Big Data and has raised $1.5 million to advance its ambitions.
Philip Bourne joins NIH from UC San Diego where he uses data mining in pharmacology. He is known to support the free exchange of scientific data.
Last winter, Google Flu Trends was shown to be a work in progress when it wildly overestimated incidence of influenza, but its algorithm-based model has considerable potential.